Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis

Serçe, Nuran Bektas; Boesl, Andreas; Klaman, Irina; Serenyi, Sonja von; Noetzel, Erik; Press, Michael F.; Dimmler, Arno; Hartmann, Arndt; Sehouli, Jalid; Knuechel, Ruth; Beckmann, Matthias W.; Fasching, Peter A.; Dahl, Edgar

doi:10.1186/1471-2407-12-597

Cited by 28 publications

(34 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Potential importance of Serbp1 in tumour progression has been reported. [36][37][38][39] High resolution of cryoelectron microscopy of the 80S ribosome of human peripheral blood mononuclear cells has shown the presence of Serbp1 in the 40S subunit. 40 However, Serbp1 was not identified in the 80S ribosome of HeLa cells by using the same microscopic method 41 (although recent cross-linking The isoforms 1 and 2 of rat Serbp1 were listed as significant candidates.…”

Section: Proteomic Analysis Identified Serbp1 In the Cytoplasmic Rimentioning

confidence: 99%

The mRNA‐binding protein Serbp1 as an auxiliary protein associated with mammalian cytoplasmic ribosomes

Muto

Sugihara

Shibakawa

et al. 2018

Cell Biochemistry & Function

View full text Add to dashboard Cite

In mammalian cells, the final protein output of their genetic program is determined not only by controlling transcription but also by regulating the posttranscriptional events. Although mRNA-binding proteins and the cytoplasmic ribosome have long been recognized as central players in the posttranscriptional regulation, their physical and functional interactions are still far from a complete understanding. Here, we describe the intracellular localization of Serbp1, an mRNA-binding protein, and the inclusion of this protein in actively translating ribosomes in normal and cancer cells. These findings shed a new light into molecular mechanisms underlying Serbp1 action in translational gene regulation and tumour progression.

show abstract

Section: Proteomic Analysis Identified Serbp1 In the Cytoplasmic Rimentioning

confidence: 99%

The mRNA‐binding protein Serbp1 as an auxiliary protein associated with mammalian cytoplasmic ribosomes

Muto

Sugihara

Shibakawa

et al. 2018

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…SERBP1 has also been shown to play a crucial role in cancer (28, 31). Identifying the role of the LRH1-SERBP1-ILF3 transcriptional complex may shed light into novel function of these proteins and their involvement in cancer progression.…”

Section: Resultsmentioning

confidence: 99%

“…Although PAI-1 levels were not measured in this study, our LRH1 siRNA experiment suggests that a similar effect on PAI-1 would have been seen since SERBP1 expression was significantly increased. Pertinent to cancer, SERBP1 overexpression has been correlated with a favorable prognosis in human breast cancer (28). LRH1 has been extensively studied in breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, SERBP1 has been shown to interact with to PGRMC1, to mediate the antiapoptotic actions of the progesterone receptor, another NR (25–27). Interestingly, SERBP1 overexpression has been correlated with a favorable prognosis in human breast cancer (28). It remains to be seen whether any protein interaction between SERBP1 and LRH1 exists.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SERBP1 Is a Component of the Liver Receptor Homologue-1 Transcriptional Complex

et al. 2015

View full text Add to dashboard Cite

Liver receptor homolog-1 (LRH1) is an orphan nuclear receptor that has been shown to play a role in the transcriptional regulation of pathways involved in cancer. Elucidating the components of the LRH1 transcriptional complex to better understand endogenous regulation of the receptor as well as its role in cancer remains a high priority. A sub-cellular enrichment strategy coupled with proteomic approaches was employed to identify putative LRH1 coregulators. Nuclear fractionation protocol was essential for detection of LRH1 peptides by mass spectrometry (MS), with most peptides being observed in the insoluble fraction (receptor bound to DNA). SERBP1 and ILF3 were identified as LRH1 interacting partners by both western blot and MS/MS analysis. Receptor knockdown by siRNA showed an increased in SERBP1 expression while ILF3 expression was unchanged. In contrast, receptor overexpression decreased only SERBP1 mRNA levels. Consistent with these data, in a promoter:reporter assay, binding of LRH1 to the promoter region of SERBP1 resulted in a decrease in the expression level of the reporter gene, and subsequently, inhibiting transcription. Given the receptor’s role in cancer progression, the study here elucidates additional transcriptional machinery involved in LRH1 signaling and potentially provides new targets for therapeutics development.

show abstract

“…Some of the genes including SERBP1 47 , RPS12 48 , HSD17B 49 and KPNB1 50 from which the novel peptides were identified, are known to be associated with breast cancers. Many of the abnormally spliced products may not be active.…”

Section: Discussionmentioning

confidence: 99%

Distinct Splice Variants and Pathway Enrichment in the Cell-Line Models of Aggressive Human Breast Cancer Subtypes

Menon

Zhang

et al. 2013

J. Proteome Res.

View full text Add to dashboard Cite

This study was conducted as a part of the Chromosome-Centric Human Proteome Project (C-HPP) of the Human Proteome Organization. The United States team of C-HPP is focused on characterizing the protein-coding genes in chromosome 17. Despite its small size, chromosome 17 is rich in protein-coding genes, it contains many cancer-associated genes, including BRCA1, ERBB2 (Her2/neu), and TP53. The goal of this study was to examine the splice variants expressed in three ERBB2 expressed breast cancer cell line models of hormone receptor negative breast cancers by integrating RNA-Seq and proteomic mass spectrometry data. The cell-lines represent distinct phenotypic variations subtype: SKBR3 (ERBB2+ (over-expression)/ ER−/PR−; adenocarcinoma), SUM190 (ERBB2+ (over-expression)/ER−/PR−; inflammatory breast cancer) and SUM149 (ERBB2 (low expression) ER−/PR −; inflammatory breast cancer). We identified more than one splice variant for 1167 genes expressed in at least one of the three cancer cell lines. We found multiple variants of genes that are in the signaling pathways downstream of ERBB2 along with variants specific to one cancer cell line compared to the other two cancer cell lines and to normal mammary cells. The overall transcript profiles based on read counts indicated more similarities between SKBR3 and SUM190. The top-ranking Gene Ontology and BioCarta pathways for the cell-line specific variants pointed to distinct key mechanisms including: amino sugar metabolism, caspase activity, and endocytosis in SKBR3; different aspects of metabolism, especially of lipids in SUM190; cell- to-cell adhesion, integrin and ERK1/ERK2 signaling, and translational control in SUM149. The analyses indicated an enrichment in the electron transport chain processes in the ERBB2 over-expressed cell line models; and an association of nucleotide binding, RNA splicing and translation processes with the IBC models, SUM190 and SUM149. Detailed experimental studies on the distinct variants identified from each of these three breast cancer cell line models may open opportunities for drug target discovery and help unveil their specific roles in cancer progression and metastasis.

show abstract

Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis

Cited by 28 publications

References 29 publications

The mRNA‐binding protein Serbp1 as an auxiliary protein associated with mammalian cytoplasmic ribosomes

The mRNA‐binding protein Serbp1 as an auxiliary protein associated with mammalian cytoplasmic ribosomes

SERBP1 Is a Component of the Liver Receptor Homologue-1 Transcriptional Complex

Distinct Splice Variants and Pathway Enrichment in the Cell-Line Models of Aggressive Human Breast Cancer Subtypes

Contact Info

Product

Resources

About